Goldman downgraded Hamilton Lane from Neutral to Sell and set a new price target of $139.00
Save time and jump to the most important pieces.
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 5/15/2025 | Outperform → Perform | Oppenheimer | |
| 1/21/2025 | $186.00 | Perform → Outperform | Oppenheimer |
| 1/6/2025 | $139.00 | Neutral → Sell | Goldman |
| 9/12/2024 | $156.00 | Equal Weight | Wells Fargo |
| 4/11/2024 | $115.00 | Overweight → Neutral | JP Morgan |
| 1/11/2024 | Outperform → Perform | Oppenheimer | |
| 5/26/2023 | $87.00 | Perform → Outperform | Oppenheimer |
| 3/15/2023 | $85.00 | Neutral → Overweight | JP Morgan |
3 - Hamilton Lane INC (0001433642) (Issuer)
4 - Hamilton Lane INC (0001433642) (Issuer)
4 - Hamilton Lane INC (0001433642) (Issuer)
CONSHOHOCKEN, Pa., May 29, 2025 /PRNewswire/ -- Leading private markets asset management firm Hamilton Lane Incorporated (NASDAQ:HLNE) today reported its results for the fourth fiscal quarter and full fiscal year ended March 31, 2025. FISCAL YEAR 2025 HIGHLIGHTS Assets under management – Total assets under management of $138 billion grew 11% year-over-year. Fee-earning assets under management increased 10% to $72 billion over the same period.Revenue – Management and advisory fees increased 14% to $513.9 million for fiscal 2025.Carried Interest – Unrealized carried interest balance of $1.3 billion was up 3% year-over-year.Earnings per share – GAAP EPS of $5.41 on $217.4 million of GAAP net i
TEL AVIV, Israel, May 12, 2025 (GLOBE NEWSWIRE) -- Classiq today announced raising $110 million in Series C funding, the largest ever for a quantum software company. The round was led by Entrée Capital, with participation from Norwest, NightDragon, funds managed by Hamilton Lane (NASDAQ:HLNE), Clal, Neva SGR, Phoenix, Team8, IN Venture, Wing, HSBC, Samsung Next and QBeat, as well as other new and existing investors. This investment brings Classiq's total funding to $173 million, positioning the company to meet growing demand by significantly scaling its go-to-market, customer success and R&D teams. Classiq will expand its global footprint to broaden its leading role in national quantum
CONSHOHOCKEN, Pa., May 8, 2025 /PRNewswire/ -- Hamilton Lane Incorporated (NASDAQ:HLNE) is scheduled to release financial results for the fourth fiscal quarter and full fiscal year ended March 31, 2025 before the market opens on Thursday, May 29, 2025. A copy of the earnings release and full detailed presentation will be available on the Hamilton Lane Shareholders website at https://shareholders.hamiltonlane.com/. Hamilton Lane will host a conference call via webcast at 11:00 a.m. ET on May 29 to discuss the results for the fourth fiscal quarter and full fiscal year. For access to the live event via the webcast, visit Hamilton Lane's Shareholder's website by clicking here (https://sharehold
SC 13G/A - Hamilton Lane INC (0001433642) (Subject)
SC 13G/A - Hamilton Lane INC (0001433642) (Subject)
SC 13G/A - Hamilton Lane INC (0001433642) (Subject)
8-K - Hamilton Lane INC (0001433642) (Filer)
SCHEDULE 13D/A - Hamilton Lane INC (0001433642) (Subject)
SCHEDULE 13D/A - Hamilton Lane INC (0001433642) (Subject)
Oppenheimer downgraded Hamilton Lane from Outperform to Perform
Oppenheimer upgraded Hamilton Lane from Perform to Outperform and set a new price target of $186.00
Goldman downgraded Hamilton Lane from Neutral to Sell and set a new price target of $139.00
4 - Hamilton Lane INC (0001433642) (Issuer)
CONSHOHOCKEN, Pa., May 29, 2025 /PRNewswire/ -- Leading private markets asset management firm Hamilton Lane Incorporated (NASDAQ:HLNE) today reported its results for the fourth fiscal quarter and full fiscal year ended March 31, 2025. FISCAL YEAR 2025 HIGHLIGHTS Assets under management – Total assets under management of $138 billion grew 11% year-over-year. Fee-earning assets under management increased 10% to $72 billion over the same period.Revenue – Management and advisory fees increased 14% to $513.9 million for fiscal 2025.Carried Interest – Unrealized carried interest balance of $1.3 billion was up 3% year-over-year.Earnings per share – GAAP EPS of $5.41 on $217.4 million of GAAP net i
CONSHOHOCKEN, Pa., May 8, 2025 /PRNewswire/ -- Hamilton Lane Incorporated (NASDAQ:HLNE) is scheduled to release financial results for the fourth fiscal quarter and full fiscal year ended March 31, 2025 before the market opens on Thursday, May 29, 2025. A copy of the earnings release and full detailed presentation will be available on the Hamilton Lane Shareholders website at https://shareholders.hamiltonlane.com/. Hamilton Lane will host a conference call via webcast at 11:00 a.m. ET on May 29 to discuss the results for the fourth fiscal quarter and full fiscal year. For access to the live event via the webcast, visit Hamilton Lane's Shareholder's website by clicking here (https://sharehold
RED BANK, N.J., April 17, 2025 /PRNewswire/ -- PAX Health, a leading behavioral healthcare company backed by HCAP Partners and funds managed by Hamilton Lane (NASDAQ:HLNE), today announced its acquisition of Richardson Psychiatric Associates, a comprehensive outpatient psychiatric practice serving adults, adolescents, children, and families. This strategic acquisition enhances PAX Health's portfolio of mental health services and expands its geographic footprint in Western Pennsylvania, strengthening the company's ability to deliver high-quality psychiatric care across diverse
Grenova, Inc., a Virginia-based innovator in sustainable laboratory technologies, today announced two significant milestones for the company: the appointment of Ted Hull to Grenova's board, and the successful completion of a new round of growth equity capital. These developments support Grenova's strategic vision to drive innovation, expand automation capabilities, and deliver transformative solutions to laboratories worldwide. Ted Hull brings over 30 years of experience in the life sciences industry, including as a clinical lab CEO for the last 20+ years. In his role at Grenova, Mr. Hull is set to provide strategic leadership and to play a pivotal role in shaping the company's future. "I
Industry leader with 35+ years of experience in manufacturing operations and global supply chain excellence Cosette Pharmaceuticals, Inc., a leading specialty pharmaceuticals company, today announced the appointment of Vincent (Vin) Colicchio as Senior Vice President of Operations, effective February 3, 2025. In this role, Vin will lead Cosette's manufacturing, global supply chain, and operational strategy, ensuring efficiency, and supply continuity as the company continues its strong trajectory of growth and transformation. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250210366017/en/Senior Vice President, Operations (Photo
Experienced commercial leader joins Cosette to drive the next phase of growth and transformation Cosette Pharmaceuticals, Inc., a leading specialty pharmaceuticals company, today announced the appointment of Brad Leonard as Vice President, Generics Commercial Operations. In this role, Brad will spearhead Cosette's generics business, including Generics Sales, Marketing/Pricing, Customer Service, and Demand Planning, as the company continues its expansion in these markets. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250203104224/en/Brad Leonard, Vice President, Generics Commercial Operations (Photo: Business Wire) "Cosette is